Compound Planning Inc. Purchases 10,941 Shares of Pfizer Inc. $PFE

Key Points

• Compound Planning Inc. increased its holdings in Pfizer Inc. by 32.9% during the first quarter, bringing its total shares to 44,228, valued at approximately $1,121,000.
• Other institutional investors, including Bessemer Group Inc. and Capital Advisors Inc. OK, also raised their stakes in Pfizer during the same period, with institutional ownership now at 68.36%.
• Pfizer recently reported a quarterly earnings per share of $0.78, surpassing expectations, and announced a quarterly dividend of $0.43, yielding 6.7% annually.

Compound Planning Inc. raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 32.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,228 shares of the biopharmaceutical company's stock after acquiring an additional 10,941 shares during the period. Compound Planning Inc.'s holdings in Pfizer were worth $1,121,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Clarity Asset Management Inc. purchased a new stake in Pfizer in the 4th quarter worth about $27,000. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth about $27,000. North Capital Inc. purchased a new stake in Pfizer in the 1st quarter worth about $28,000. Finally, Bayforest Capital Ltd purchased a new stake in Pfizer in the 1st quarter worth about $28,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 2.8%

Shares of Pfizer stock traded down $0.73 during midday trading on Monday, reaching $25.15. 32,304,503 shares of the company's stock traded hands, compared to its average volume of 44,473,524. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The company has a market cap of $142.99 billion, a PE ratio of 13.38, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. The stock has a 50 day moving average of $24.72 and a 200-day moving average of $24.39. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the prior year, the company earned $0.60 earnings per share. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on PFE shares. Leerink Partners decreased their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Wolfe Research lifted their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. The Goldman Sachs Group lifted their target price on Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Finally, UBS Group lifted their target price on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.